COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN COLOMBIA

被引：1
|
作者：
Nunez, S. M. [1 ]
Mould-Quevedo, J. F. [2 ]
Gutierrez-Ardila, M., V [1 ]
Roberts, C. S. [2 ]
La Rotta, J. E. [1 ]
机构：
[1] Pfizer Colombia, Bogota, Cundinamarca, Colombia
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1304
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A242 / A242
页数：1
相关论文
共 50 条
  • [31] Policy Statement-Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)
    Bocchini, Joseph A., Jr.
    Bradley, John S.
    Brady, Michael T.
    Bernstein, Henry H.
    Byington, Carrie L.
    Fisher, Margaret C.
    Glode, Mary P.
    Jackson, Mary Anne
    Keyserling, Harry L.
    Kimberlin, David W.
    Orenstein, Walter A.
    Schutze, Gordon E.
    Willoughby, Rodney E., Jr.
    PEDIATRICS, 2010, 126 (01) : 186 - 190
  • [32] THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A427 - A427
  • [33] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [34] Immunogenicity of sequential 13-valent conjugated and 23-valent unconjugated pneumococcal vaccines in a population of children with lupus
    Gorelik, M.
    Elizalde, A.
    Williams, K. Wong
    Gonzalez, E.
    Cole, J. L.
    LUPUS, 2018, 27 (14) : 2228 - 2235
  • [35] COST EFFECTIVENESS OF PCV13 VS PPSV23 FOR THE IMMUNIZATION OF ADULTS OVER 65 YEARS WITH LOW OR MODERATE RISK OF PNEUMOCOCCAL INFECTION
    Baez-Revueltas, F. B.
    Laredo, F.
    VALUE IN HEALTH, 2017, 20 (09) : A931 - A931
  • [36] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Atwood, Mark
    Beausoleil, Linda
    Breton, Marie-Claude
    Laferriere, Craig
    Sato, Reiko
    Weycker, Derek
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2018, 109 (5-6): : 756 - 768
  • [37] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [38] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Mark Atwood
    Linda Beausoleil
    Marie-Claude Breton
    Craig Laferriere
    Reiko Sato
    Derek Weycker
    Canadian Journal of Public Health, 2018, 109 : 756 - 768
  • [39] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [40] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Perdrizet, Johnna
    Horn, Emily K.
    Nua, Winniefer
    Perez-Peralta, Judith
    Nailes, Jennifer
    Santos, Jaime
    Ong-Lim, Anna
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2625 - 2642
12345